Advertisement

Topics

Latest "Materialise" News Stories

21:53 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Materialise" found in our extensive news archives from over 250 global news sources.

More Information about Materialise on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Materialise for you to read. Along with our medical data and news we also list Materialise Clinical Trials, which are updated daily. BioPortfolio also has a large database of Materialise Companies for you to search.

Showing "Materialise" News Articles, all 11

Wednesday 6th March 2019

Materialise Reports Full Year and Fourth Quarter 2018 Results

Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software and of sophisticated 3D printing services, today announced its financial results for the full year and fourth quarter ended December 31, 2018. Highlights – Full Year and Fourth Quarter 2018 Full Year 2018: Total reven...


Friday 25th January 2019

Materialise NV MTLS Medical Equipment Deals and Alliances Profile [Report Updated: 14122018] Prices from USD $250

SummaryMaterialise NV Materialise is a technology company that offers additive manufacturing software and 3D printing solutions. The company's products comprise the factory for 3D printing, rapid Fit, solutions for machine developers, biomedical engineering software, software for additive manufacturing, biomedical engineering solutions, surgical solutions for orthopaedics surgeons and craniomaxill...

Wednesday 16th January 2019

Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Phase 3 SPARTAN data served as basis for approval, which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years1 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted...


Monday 7th January 2019

Janssen Submits Application to European Medicines Agency Seeking Approval of STELARA® (ustekinumab) for Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

If approved, ustekinumab will be the first interleukin (IL)-12/23 inhibitor licensed for the treatment of ulcerative colitis The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of STELARA® (ustekinumab) for the trea...

Thursday 20th December 2018

Janssen Announces European Commission Approval of Darzalex®▼ (daratumumab) Split Dosing Regimen

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation to provide healthcare professionals with the option to split the first infusion of Darzalex® (daratumumab) over two consecutive days. “We are committed to the development of new treatments, combinations, and formulations that will support people liv...

Wednesday 28th November 2018

AEVIS VICTORIA SA: Adjusted revenues at 30 September 2018 amounted to CHF 473.7 million

AEVIS VICTORIA SA / Key word(s): 9 Month figures 28-Nov-2018 / 17:49 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Press release Fribourg, 28 November 2018 AEVIS VICTORIA SA - Adjusted revenues at 30 September 2018 amounted to CHF 473.7 million As at 30 September 2018, total revenues of AEVIS V...

Materialise validates Stratasys 3D printers for patient-specific anatomical models

The move expands Stratasys’ suite of printers and materials validated by its collaborator Materialise as part of FDA-cleared Materialise Mimics inPrint software. It brings a new 3D printing system The post Materialise validates Stratasys 3D printers for patient-specific anatomical models appeared first on Compelo Medical Devices.

Tuesday 27th November 2018

Stratasys and Materialise bring 3D printed medical models to life

Further bringing 3D printed medical models to life, Stratasys is expanding the suite of printers and materials validated by its collaborator Materialise as part of FDA-cleared Materialise Mimics inPrint software.

Monday 26th November 2018

Stratasys and Materialise: 3D Printed Medical Models Come to Life

Stratasys PolyJet technology and Materialise FDA-cleared software now most versatile 3D printing system for hospitals and physicians to build anatomical models at the point-of-care Further bringing 3D printed medical models to life, Stratasys (Nasdaq: SSYS) is expanding the suite of printers and materials validated by its collaborator

Wednesday 14th November 2018

Janssen Seeks Expanded Use of IMBRUVICA®▼ (ibrutinib) in Two Indications in Europe

Applications submitted to the European Medicines Agency (EMA) for new combinations in adult patients with chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinemia (WM) The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two Type II variation applications to the European Medicines Agency (EMA) ...

Wednesday 7th November 2018

3D Printing Metals Market by Form Powder and Filament, Type Titanium, Nickel, Stainless Steel, Aluminum, EndUse Industry Aerospace Defense, Automotive, Medical Dental, and Region APAC, North America, Europe, MEA, SA Global Forecast to 2023 [Report Upda

The 3D printing metals market is projected to grow at a CAGR of 28.8% from 2018 to 2023The 3D printing metals market is projected to grow from USD 590.4 million in 2018 to USD 2,089.7 million by 2023, at a CAGR of 28.8% from 2018 to 2023. The increasing application of 3D printing in aerospace defense industry, majorly in the manufacturing of aircraft engines and components, as well as the expiry ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks